journal
https://read.qxmd.com/read/38041755/correction-to-evaluation-of-bruton-tyrosine-kinase-inhibitors-monotherapy-and-combination-therapy-in-lymphocytic-leukemia
#1
Xiangxing Liu, Binyi Hu, Nan Peng, Liming Chen, Dingyuan Hu, Jiaojiao Zhang, Lijue Wang, Zhenwei Xie, Suping Niu, Qian Lu, Jin Lu, Yi Fang
No abstract text is available yet for this article.
December 2, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37985534/correction-to-diagnosis-of-interstitial-lung-disease-ild-secondary-to-systemic-sclerosis-ssc-and-rheumatoid-arthritis-ra-and-identification-of-progressive-pulmonary-fibrosis-using-chest-ct-a-narrative-review
#2
Antonio Poerio, Eleonora Carlicchi, Maurizio Zompatori
No abstract text is available yet for this article.
November 20, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37979127/real-life-diagnostic-and-therapeutic-approach-to-cll-a-2022-update-from-an-expert-panel-in-tuscany
#3
REVIEW
Claudia Baratè, Alessandro Sanna, Edoardo Benedetti, Monica Bocchia, Enrico Capochiani, Romano Danesi, Sabrina Moretti, Ubaldo Occhini, Simone Santini, Sara Galimberti, Alessandro Gozzetti
A panel of chronic lymphocytic leukemia (CLL) experts from Tuscany propose a real-life diagnostic and therapeutic approach CLL that considers the role of genomic and somatic prognostic factors in risk stratification and treatment decisions. Safety and efficacy of new agents has been demonstrated now not only in clinical trials but also in many real-world series. The BTK inhibitors, ibrutinib and acalabrutinib, and BH3 mimetic venetoclax are now indicated as first-line therapy and chemoimmunotherapy can be spared to the majority of CLL patients, thus preventing unnecessary hematological and non-hematological toxicity and second primary tumors...
November 18, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37979126/clinical-and-imaging-features-of-lymphomatosis-cerebri-analysis-of-8-cases-and-systematic-review-of-the-literature
#4
JOURNAL ARTICLE
Mengke Fan, Lu Zhao, Qingjiang Chen, Mingzhi Zhang, Xudong Zhang, Zhihao Yang, Suxiao Li, Yunfei Song
Lymphomatosis cerebri (LC) is a rare type of primary central nervous system lymphoma with diffuse, nonenhancing infiltrative lesions and is often misdiagnosed. Our study aimed to investigate the clinical characteristics and prognosis of LC through analyzing patients from the literature and our own center, so as to improve early diagnosis and treatment. PubMed, Web of Science and our hospital databases were reviewed, and information on demographic, clinical, pathological, cerebrospinal fluid (CSF), neuroimaging and treatment options was extracted...
November 18, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37973619/vaccine-effectiveness-of-covid-19-and-rebound-in-the-real-world
#5
JOURNAL ARTICLE
Myung-Bae Park, Boram Sim
We intend to evaluate the relationship between the rates of global SARS-CoV-2 vaccination and the number of COVID-19 confirmed cases, as well as the mortality rate after the declaration of a pandemic. Of the data from 191 countries at the time of data retraction, we selected 111 countries that have SARS-CoV-2 vaccination reports. We stratified countries into high-income and non-high-income countries (HIC and non-HIC) based on World Bank income-group. We used a fixed-effects model (FEM) and performed a longitudinal analysis...
November 16, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37966552/emt-induced-immune-evasion-connecting-the-dots-from-mechanisms-to-therapy
#6
REVIEW
Sikiru O Imodoye, Kamoru A Adedokun
Epithelial-mesenchymal transition (EMT) is a dynamic program crucial for organismal development and tissue regeneration. Unfortunately, this program is often hijacked by epithelial tumors to facilitate metastasis. Beyond its role in cancer spread, EMT increases cancer cell survival by activating stem cell programs and bypassing apoptotic programs. Importantly, the capacity of EMT to enforce tumor progression by altering the tumor cell phenotype without triggering immune responses opens the intriguing possibility of a mechanistic link between EMT-driven cancers and immune evasion...
November 15, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37943410/far-in-systemic-lupus-erythematosus-a-potential-biomarker-of-disease-activity-and-lupus-nephritis
#7
JOURNAL ARTICLE
Jili Xu, Hongmei Zhang, Nan Che, Hengjin Wang
The fibrinogen-to-albumin ratio (FAR), a novel inflammatory marker, has been studied in various diseases. However, the significance of FAR in systemic lupus erythematosus (SLE) has not been fully elucidated. This study was to investigate the connection between FAR and SLE. A retrospective analysis of 154 SLE patients and 77 healthy individuals was performed. The clinical and laboratory data were reviewed. Receiver operating characteristic (ROC) curves were conducted for FAR at baseline to predict disease activity and lupus nephritis (LN) in SLE patients...
November 9, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37940724/treatment-outcomes-of-patients-with-classic-and-aids-related-kaposi-sarcoma-a-single-center-real-world-experience
#8
JOURNAL ARTICLE
Bryan Valcarcel-Valdivia, Daniel Enriquez-Vera, Luis Enrique Piedra, Alexis Holguín, Gabriel De la Cruz Ku
The recommended first-line chemotherapy agents for managing Kaposi sarcoma (KS) in high-income countries are expensive and often unavailable in developing nations such as Peru. Limited data exist on whether management practices in these countries affect patient outcomes. We assessed the real-world treatment approaches and outcomes of patients with KS in Peru. We retrospectively reviewed the medical records of patients with acquired immunodeficiency syndrome-related KS (AIDS-related KS; n = 95) and classic KS (CKS; n = 81) diagnosed at a tertiary center between 2000 and 2014 in Lima, Peru...
November 9, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37938466/prognostic-impact-of-absolute-peripheral-blood-nk-cell-count-after-four-cycles-of-r-chop-like-regimen-treatment-in-patients-with-diffuse-large-b-cell-lymphoma
#9
JOURNAL ARTICLE
Zhongjun Huo, Fang Chen, Jiajia Zhao, Ping Liu, Zhi Chao, Kang Liu, Ji Zhou, Dan Zhou, Lu Zhang, Haifeng Zhen, Wenqun Yang, Zhenqing Tan, Kaibo Zhu, Zimian Luo
As a subtype of lymphocyte, natural killer (NK) cell is the first line of defense that shows a strong function in tumor immunotherapy response and clinical outcomes. The current study aims to investigate the prognostic influence of peripheral blood absolute NK cell count after four cycles of rituximab combined with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment (NKCC4) in diffuse large B cell lymphoma (DLBCL) patients. A total of 261 DLBCL patients treated with R-CHOP from January 2018 to September 2022 were enrolled...
November 8, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37938465/immune-profile-alterations-of-systemic-lupus-erythematosus-patients-with-infections
#10
JOURNAL ARTICLE
Langxian Zhi, Liyang Gu, Lei Tong, Xuesong Liu, Liangjing Lu, Ruru Guo
This study aimed to elucidate the immune status of systemic lupus erythematosus (SLE) patients with infections. We enrolled 253 SLE patients including 77 patients with infections. Clinical features and immunological parameters were analyzed, with particular reference to neutrophil CD64 (nCD64) expression, myeloid-derived suppressor cells (MDSCs), activated T cells and multiple cytokines. Among the 77 SLE patients with infections, 32 patients (41.56%) developed fever and 20 patients (25.97%) developed serositis, which were higher compared to the non-infection group...
November 8, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37935952/pan-pi3k-inhibition-with-copanlisib-overcomes-treg-and-m2-tam-mediated-immune-suppression-and-promotes-anti-tumor-immune-responses
#11
JOURNAL ARTICLE
Simon Heller, Sarah Glaeske, Katja Gluske, Juliane Paul, Annika Böhme, Andreas Janzer, Helge Gottfried Roider, Anna Montebaur, Barbara Nicke, Ralf Lesche, Oliver von Ahsen, Oliver Politz, Ningshu Liu, Mátyás Gorjánácz
The PI3K pathway is one of the most frequently altered signaling pathways in human cancer. In addition to its function in cancer cells, PI3K plays a complex role in modulating anti-tumor immune responses upon immune checkpoint inhibition (ICI). Here, we evaluated the effects of the pan-Class I PI3K inhibitor copanlisib on different immune cell types in vitro and on tumor growth and immune cell infiltration in syngeneic murine cancer models. Intermittent treatment with copanlisib resulted in a strong in vivo anti-tumor efficacy, increased tumor infiltration of activated T cells and macrophages, and increased CD8+  T cell/regulatory T cell and M1/M2 macrophage ratios...
November 8, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37930607/tacrolimus-shows-adequate-efficacy-in-patients-with-antiphospholipid-antibodies-associated-thrombocytopenia-a-retrospective-cohort-study
#12
JOURNAL ARTICLE
Yu Shi, Can Huang, Yangzhong Zhou, Hui Jiang, Yongqiang Zhao, Mengtao Li, Xiaofeng Zeng, Jiuliang Zhao
Thrombocytopenia is a common manifestation associated with the presence of antiphospholipid antibodies (aPL). The aim of this study is to investigate the efficacy and safety of tacrolimus treatment in aPL associated thrombocytopenia. This is a single-center retrospective study. Patients who had persistent positive aPL and thrombocytopenia that was treated with tacrolimus were included. A total of 49 patients [38 females (77.6%)] were enrolled from Nov 2013 to Apr 2022 with a median treatment duration of 22 months...
November 6, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37930606/circzbtb46-predicts-poor-prognosis-and-promotes-disease-progression-of-myelodysplastic-syndromes-and-acute-myeloid-leukemia
#13
JOURNAL ARTICLE
Shuang Li, Guangjie Zhao, Wanling Wu, Nianyi Li, Qian Wang, Wei Wang, Xianmin Song, Xiaoqin Wang
Circular RNAs (circRNAs) have been recently identified as important regulators of various diseases, especially cancer. However, the roles of circRNAs in hematologic malignancies have been rarely reported. This study aimed to identify a specific circRNA expression profile in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and to evaluate the biological roles of circRNA in MDS and AML for understanding their clinical significance. Reverse transcription-quantitative PCR was performed to validate the expression of circZBTB46...
November 6, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37930605/a-novel-immune-checkpoint-related-signature-for-prognosis-and-immune-analysis-in-breast-cancer
#14
JOURNAL ARTICLE
Haihong Hu, Ting Yan, Hongxia Zhu, Wendi Zhan, Jingdi Zhang, Siyu Wang, Lingxiang Jiang, David Escobar, Taolan Zhang
Breast cancer is one of the most prevailing forms of cancer globally. Immunotherapy has demonstrated efficacy in improving the overall survival of breast cancer. The aim of us was to formulate a novel signature predicated on immune checkpoint-related genes (ICGs) that could anticipate the prognosis and further analyze the immune status of patients with breast cancer. After acquiring data, we pinpointed the definitive ICGs for constructing the prognostic model of breast cancer. We constructed a novel prognostic model and created a fresh risk score called Immune Checkpoint-related Risk Score in breast cancer (ICRSBC)...
November 6, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37930604/reduced-regulatory-effects-of-bone-marrow-derived-mesenchymal-stem-cells-on-activated-t-lymphocytes-and-th1-th2-cytokine-secretion-in-children-with-aplastic-anemia
#15
JOURNAL ARTICLE
Xiaoping Guo, Wenwen Weng, Yuwen Wang, Jin Pan, Sisi Li, Yuanyuan Chen, Hua Song, Jingying Zhang, Weiqun Xu, Xiaojun Xu, Yongmin Tang
Acquired aplastic anemia (AA) is a recognized immune-mediated disorder and abnormally activated T lymphocyte-mediated bone marrow destruction is considered to be its main pathogenesis. Whether abnormal activation of T lymphocytes would also damage bone marrow-derived MSCs remains to be further studied. The aim of this study was to analyze the extent of T lymphocyte activation and the levels of Th1/Th2 cytokines of AA patients, and to explore the immunomodulatory effects of BM-MSCs on IL-2-stimulated T lymphocyte activation and cytokine production in vitro by means of transwell co-culture assay and flow cytometry measurement...
November 6, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37925683/a-novel-auxiliary-diagnostic-model-for-covid-19-screening-using-enzymes-based-detection-of-serum-biomarkers-and-clinical-characteristics
#16
JOURNAL ARTICLE
Lang Yi, Shuai Peng, Peilin Liu, Xianghui Liang, Qian Gao
The screening for the coronavirus disease 2019 (COVID-19) based on virus nuclear acid detection and radiology has encountered unprecedented difficulties due to the shortage of kits and facilities, and the lack of sensitivity and specificity, especially for developing countries. The study aimed to develop an auxiliary diagnostic score based on age, biomarkers, clinical characteristics (ABC) to rapidly and accurately screen COVID-19. Serum biomarkers were detected by enzymes catalyzed reaction method which is rapid and accurate...
November 5, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37925380/efficacy-and-safety-of-orelabrutinib-based-regimens-in-diffuse-large-b-cell-lymphoma-a-single-center-retrospective-analysis
#17
JOURNAL ARTICLE
Ruowen Wei, Yingying Wu, Shan Jiang, Ao Zhang, Lu Zhang, Ling Liu, Yadan Wang, Min Zhang, Heng Mei, Fang Liu, Linghui Xia, Guohui Cui, Jun Fang
Currently, combining chemotherapy with Bruton tyrosine kinase inhibitors (BTKi) has demonstrated significant effectiveness in treating patients with diffuse large B-cell lymphoma. Orelabrutinib is a second-generation BTK inhibitor, and presently, there have been few reports of Orelabrutinib being used to treat DLBCL. We conducted a retrospective investigation to explore the safety and efficacy of Orelabrutinib in combination with chemotherapy or immunotherapy. The study comprised 19 patients with a median age of 61 years...
November 4, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37925379/cytokine-levels-in-patients-with-non-m3-myeloid-leukemia-are-key-indicators-of-how-well-the-disease-responds-to-chemotherapy
#18
JOURNAL ARTICLE
Rui Hu, Xiaosui Ling, Tonghua Yang, Jinping Zhang, Xuezhong Gu, Fan Li, Heng Chen, Yan Wen, Zengzheng Li, Yunlian Zou, Yunyun Du
Acute myeloid leukemia (AML) is a malignant hematological neoplastic disease. Autocrine or paracrine cytokines released by leukemic cells regulate the proliferation of AML cells. It is uncertain whether cytokines can indicate whether patients with AML are in remission with chemotherapy. The goal of this study was to evaluate the levels of Th1/Th2/Th17 cytokines in AML patients before and after chemotherapy to determine whether the cytokine levels could predict disease remission after chemotherapy. It was found that the levels of IL-5, IL-6, IL-8, IL-10, TNF-α, TNF-β, IL-17F, and IL-22 were significantly increased at the time of AML diagnosis in patients who achieved remission after two chemotherapy treatments (P < 0...
November 4, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37924455/a-systematic-review-regarding-the-prevalence-of-malignancy-in-patients-with-the-hyper-ige-syndrome
#19
JOURNAL ARTICLE
Tayebeh Mohammadi, Gholamreza Azizi, Hosein Rafiemanesh, Pouria Farahani, Matineh Nirouei, Marzieh Tavakol
The hyper-immunoglobulin E syndrome (HIES) is a primary immunodeficiency disease originally described as Job syndrome. The fundamental causative variant of the HIES is an autosomal dominant mutation in the signal transducer and activator of transcription 3 (STAT3) gene. It is characterized by recurrent staphylococcal cold skin abscess, sinopulmonary infection, eczema, head and face anomalies, frequent bone fractures, eosinophilia and extremely high serum IgE levels (IgE ≥ 2000 IU/mL). However, multiple other genetic defects are also known as HIES-like disorders...
November 4, 2023: Clinical and Experimental Medicine
https://read.qxmd.com/read/37921874/microrna-as-a-potential-biomarker-for-systemic-lupus-erythematosus-pathogenesis-and-targeted-therapy
#20
REVIEW
Urshila Naithani, Priyanjal Jain, Aastha Sachan, Prachi Khare, Reema Gabrani
Systemic lupus erythematosus (SLE) is an autoimmune disease associated with hyperactive innate and adaptive immune systems that cause dermatological, cardiovascular, renal, and neuropsychiatric problems in patients. SLE's multifactorial nature and complex pathogenesis present significant challenges in its clinical classification. In addition, unpredictable treatment responses in patients emphasize the need for highly specific and sensitive SLE biomarkers that can assist in understanding the exact pathogenesis and, thereby, lead to the identification of novel therapeutic targets...
November 3, 2023: Clinical and Experimental Medicine
journal
journal
38106
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.